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Multiple sclerosis (MS) is characterized by macrophage accumulation and inflammatory 
infiltrates into the CNS contributing to demyelination. Because purinergic P2X7 receptor 
(P2X7R) is known to be abundantly expressed on cells of the hematopoietic lineage 
and of the nervous system, we further investigated its phenotypic expression in MS 
and experimental autoimmune encephalomyelitis conditions. By quantitative reverse 
transcription polymerase chain reaction and flow cytometry, we analyzed the P2X7R 
expression in human mononuclear cells of peripheral blood from stable and acute 
relapsing-remitting MS phases. Human monocytes were also challenged in  vitro with 
pro-inflammatory stimuli such as the lipopolysaccharide, or the P2X7R preferential 
agonist 2′(3′)-O-(4 Benzoylbenzoyl)adenosine 5′-triphosphate, before evaluating P2X7R 
protein expression. Finally, by immunohistochemistry and immunofluorescence confocal 
analysis, we investigated the P2X7R expression in frontal cortex from secondary pro-
gressive MS cases. We demonstrated that P2X7R is present and inhibited on peripheral 
monocytes isolated from MS donors during the acute phase of the disease, moreover 
it is down-regulated in human monocytes after pro-inflammatory stimulation in  vitro. 
P2X7R is instead up-regulated on astrocytes in the parenchyma of frontal cortex from 
secondary progressive MS patients, concomitantly with monocyte chemoattractant pro-
tein-1 chemokine, while totally absent from microglia/macrophages or oligodendrocytes, 
despite the occurrence of inflammatory conditions. Our results suggest that inhibition of 
P2X7R on monocytes and up-regulation in astrocytes might contribute to sustain inflam-
matory mechanisms in MS. By acquiring further knowledge about P2X7R dynamics and 
identifying P2X7R as a potential marker for the disease, we expect to gain insights into 
the molecular pathways of MS.
Keywords: astrocytes, monocyte chemoattractant protein-1, monocytes, multiple sclerosis, neuroinflammation, 
P2X7 receptor
Abbreviations: BzATP, 2′(3′)-O-(4-Benzoylbenzoyl)adenosine 5′-triphosphate; CD, cluster of differentiation; CFA, complete 
Freund’s adjuvant; EAE, experimental autoimmune encephalomyelitis; GFAP, glial fibrillary acidic protein; HD, healthy donors; 
LPS, lipopolysaccharide; MBP, myelin basic protein; MHC II, major histocompatibility complex II; MS, multiple sclerosis; NDS, 
normal donkey serum; PBMCs, peripheral blood mononuclear cells; P2X7R, P2X7 receptor; RT-qPCR, quantitative reverse 
transcription polymerase chain reaction; SPMS, secondary progressive MS.
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inTrODUcTiOn
Peripheral and central mechanisms provide insights into the cellu-
lar basis of neuroinflammation that leads to severe demyelination 
and neurodegeneration in multiple sclerosis (MS). During both 
MS and experimental autoimmune encephalomyelitis (EAE), 
monocyte-derived macrophages are part of the inflammatory 
CNS infiltrates and accumulate during the disease concomitantly 
with active demyelination, while CNS-resident microglia-derived 
macrophages are inert at disease onset and participate to later 
phases of the disease. Autoreactive myelin-specific T cells then 
boost inflammation, demyelination and CNS damage, contribut-
ing to neurological deficit, and blood–brain barrier dysfunction 
(1). In addition, astrocytes appear to have a dual role in MS, 
depending on the disease status and lesion topography, and 
contributing in both pathogenic alterations and beneficial repair 
(2–6). In examining those mechanisms that converge in caus-
ing inflammatory demyelination, the analysis of frontal cortex 
constitutes a convenient experimental platform, because profuse 
lesions in cerebral cortex constitute a significant proportion of 
MS pathology, and characterize the evolution from a relapsing/
remitting early phase into a secondary progressive MS (SPMS) 
(7–9).
Extracellular purine/pyrimidine nucleotides and nucleo-
sides binding to several different purinergic receptors are 
among the most diffuse exogenous signals playing important 
biological functions in the CNS, being responsible for the 
cell-to-cell communication under normal and pathological 
conditions (10–14). A member of the purinergic P2X family 
of ATP-gated ion channels, the P2X7 receptor (P2X7R) (15) 
is selectively expressed on cells of the hematopoietic lineage 
(16–19). Moreover, in the nervous system, P2X7R is present on 
activated microglia (20–22), astrocytes (23–25), oligodendro-
cytes (26–28), Schwann cells (29), and neurons (30). Despite 
its wide expression in many cell types participating to MS, only 
incomplete information is available regarding P2X7-mediated 
signaling in the disease. For instance, in optic nerve P2X7R 
expression is augmented in oligodendrocytes and myelin 
sheaths in MS and EAE before lesion formation, thus contrib-
uting to tissue damage; as a consequence, P2X7R blockade 
prevents oligodendrocyte excitotoxicity and ameliorates EAE 
(31). P2X7R immunoreactivity is augmented also in activated 
microglia/macrophages in spinal cord during MS, and extra-
cellular ATP apparently contributes to MS lesion-associated 
release of interleukin-1β from microglia/macrophages, via 
P2X7R-dependent induction of cyclooxygenase-2 and down-
stream pathogenic mediators (21). Mice deficient in P2X7R 
function are more resistant to EAE than wild-type mice, also 
showing reduced CNS inflammation, axonal damage, and 
astrocytes activation (32). Furthermore, pharmacological 
blockade of the receptor remarkably diminishes astrogliosis 
in rat EAE and alleviates neurological symptoms (24). On the 
other hand, it was also reported that P2X7R knockdown causes 
a more severe EAE and that lymphocyte from P2X7R−/− mice 
proliferate more vigorously in vitro, producing reduced levels 
of IFN-γ and NO, thus suggesting an important role for this 
receptor in MS lymphocyte homeostasis (33).
The aim of the present work is to further investigate the role 
of P2X7R in MS pathogenesis, by analyzing its expression in 
peripheral blood mononuclear cells (PBMCs) from stable and 
acute phases of relapsing-remitting MS and in human frontal 
cortex of SPMS.
MaTerials anD MeThODs
ethical statement
Blood samples were obtained following acquisition of the study 
participants’ informed consent. The protocol was approved by 
ethic committees of San Camillo Forlanini Hospital. Patients 
enrolled were diagnosed with relapsing-remitting form of MS 
according to 2005-revised McDonald’s criteria (34). Frontal 
cortex tissue was collected postmortem by UK MS Tissue Bank at 
Imperial College, London, and procedures for retrieval, process-
ing, and storage have gained ethical approval.
Flow cytometry and human Monocytes 
separation
Peripheral blood mononuclear cells were isolated by a density 
gradient centrifugation over a Ficoll-Hypaque (Ficoll-Paque 
PLUS, GE Healthcare) from 20  ml of freshly venous blood 
from five healthy donors (HD), five relapsing MS patients 
(MS acute), and five remitting MS patients (MS stable). Cells 
were stained with pre-titrated Abs, to evaluate the expression 
of P2X7R within cluster of differentiation 14 (CD14)-positive 
cells. Briefly, PBMCs (1  ×  106) were incubated with P2X7-
extracellular epitope antibody (Alomone Labs, Jerusalem, 
Israel) for 30  min at 4°C. Cells were washed and stained 
with goat anti-rabbit Alexa Fluor 488-conjugated antibody 
(Invitrogen, Life Technologies, Monza, MB, Italy), 30  min at 
4°C. Cells were washed and stained with anti-CD14 PE (Dako, 
Aurogene, Rome, Italy) and Live Dead Fixable Aqua Dead Cell 
Stain Kit (Invitrogen) for 30 min at 4°C.
Monocytes were isolated from PBMCs of HD by using 
Magnetic Separation with Negative Selection Columns (Miltenyi 
Biotec, Calderara di Reno, BO, Italy) according to the product 
manual. Purified monocytes (6 × 106) were cultured in serum-
free RPMI 1640 with L-Glutamine, 50 U/ml penicillin, 50 µg/ml 
streptomycin in 96-well plates.
FACS analysis was performed with FACS CyAn (Beckman 
Coulter, Pasadena, CA, USA) and with advanced flow cytometry 
software FlowJo (Tree Star, Ashaland, OR, USA).
Quantitative reverse Transcription 
Polymerase chain reaction (rT-qPcr)
Human and rat monocytes or snap-frozen tissues were homog-
enized in TRIzol (Life Technologies) and total RNA was extracted 
following the manufacturer’s instructions. UV spec trophotometric 
analysis of nucleic acids was performed by Nanodrop spectro-
photometer at 260 nm to determine concentration. The 260:280 
absorbance ratio was used to assess nucleic acids purity. After 
DNase treatment (Qiagen, Hilden, Germany), 1 µg of total RNA 
was subjected to retro-transcription by high-capacity RNA-to-
cDNA kit (Applied Biosystem, Life Technologies).
Table 1 | List of primer sequences used in this study.
Primer,  
F: forward primer, 
r: reverse primer
sequence, 5′ to 3′ Type of 
analysis
Rat P2rx7 F CTGGTGTCCTGCTGAGGAAG RT-qPCR
Rat p2rx7 R CTCGTAGTATAGTTGTGGCCCG RT-qPCR
Human P2rx7 F ATACAGTTTCCGTCGCCTTG RT-qPCR
Human P2rx7 R AACGGATCCCGAAGACTTTT RT-qPCR
Rat Il-6 F GAGGATACCACCCACAACAGACC RT-qPCR
Rat Il-6 R CAGTGCATCATCGCTGTTCATACA RT-qPCR
Rat GAPDH F GCATCTTCTTGTGCAGTGCC RT-qPCR
Rat GAPDH R TACGGCCAAATCCGTTCACA RT-qPCR
Human GAPDH F TCTTTTGCGTCGCCAGCCGAG RT-qPCR
Human GAPDH R TGACCAGGCGCCCAATACGAC RT-qPCR
RT-qPCR, quantitative reverse transcription polymerase chain reaction.
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Quantitative polymerase chain reaction was carried out using 
SYBR green (Applied Biosystem, Life Technologies) incorpora-
tion with gene-specific primers (Table 1). Relative gene expres-
sion was calculated by ΔΔCt analysis relative to GAPDH.
eae rat Model
Female Lewis rats (~160  g, 6  weeks old) were purchased from 
Charles River (Como, Italy). Animal procedures were performed 
according to European Guidelines for animal use in research 
(86/609/CEE) and requirements of Italian laws (D.L. 116/92), 
according to protocol no. 112/2014B by Italian Ministry of 
Health. Efforts were made to minimize animal suffering and the 
number of animals used.
Female rats were deeply anesthetized and injected in each hind 
paw with 100 µl of a medium containing 0.15 g/ml guinea pig 
spinal cord tissue in saline (0.9% NaCl) and complete Freund’s 
adjuvant (CFA, Sigma-Aldrich, Milan, Italy), 50% vol/vol, to 
which 5  mg/ml heat-inactivated Mycobacterium tuberculosis 
(Difco H37Ra) were added. CFA-injected rats were used as 
control of inflammation.
Starting at 5-day postinjection, all animals were daily weighed, 
assessed for clinical signs of disease, and graded according to the 
following described criteria: 0 = no clinical signs; 1 = loss of tail 
tonus; 2 =  weakness in one or both hind legs or mild paresis; 
3 =  severe paresis or paralysis of both hind legs; 4 =  severe 
paralysis of complete lower part of the body; and 5 = death due 
to aggressive EAE (35).
rat and Mouse Monocytes separation
Female C57BL/6 mice (~25 g, 8 weeks old) were purchased from 
Charles River (Como, Italy). Animal procedures were performed 
according to European Guidelines for animal use in research 
(86/609/CEE) and requirements of Italian laws (D.L. 116/92), 
according to protocol no. 119/2015PR by Italian Ministry of 
Health. Efforts were made to minimize animal suffering and the 
number of animals used.
Female Lewis rats (n =  4) and C57BL/6 mice (n =  3) were 
sacrificed by asphyxiation with CO2 and spleen excised for 
monocytes purification. CFA (n = 3) and EAE (n = 4) rats were 
sacrificed at 15 days postinjection by asphyxiation with CO2. After 
spleen harvest, single cell suspension was obtained by mechanical 
tissue dissociation in RCB buffer (NH4Cl 150  mM, NaHCO3 
10  mM, and EDTA 1  mM). Cells were plated (4 ×  106/ml) in 
RPMI, 10% fetal bovine serum, 100 U/ml gentamycin, 100 µg/ml 
streptomycin, and 100 U/ml penicillin. After 2 h, non-adherent 
cells were removed and medium enriched with 10 ng/ml rat or 
mouse macrophage colony-stimulating factor (Sigma-Aldrich) 
(36). After 1 week, cells were used for RT-qPCR, western blotting, 
and immunofluorescence analysis.
In Vitro Treatments
Human monocytes were stimulated without or with lipopolysac-
charide (LPS, Sigma-Aldrich) or 2′(3′)-O-(4-Benzoylbenzoyl)
adenosine 5′-triphosphate (BzATP, Sigma-Aldrich) for 4 h (T4) 
and 24 h (T24) at 37°C in a 5% CO2 environment. After treat-
ments, monocytes were incubated with monoclonal antibody 
as described above, to evaluate P2X7R expression by FACS 
analysis. Moreover, monocytes from control rats and mice were 
stimulated in vitro with or without LPS or BzATP for 4 h (T4) 
or 24 h (T24) and P2X7R expression was analyzed by western 
blotting.
human brain Tissue
Demographic and clinical characteristics of MS cases at the time 
of tissue collection are reported (Table 2). Frontal cortex tissues 
are from 13 neuropathological confirmed cases of MS, matched 
for disease courses (all secondary progressive MS, SPMS) but pre-
senting different ages (range 34–80 years), sex, disease durations 
(range 6–50 years), and causes of death (see Table 2). Analysis 
was performed also on samples from four patients who died by 
non-neurological diseases. Cerebral hemispheres were fixed with 
4% paraformaldehyde for 2 weeks, coronally sliced, and blocked. 
Individual blocks were cryoprotected in 30% sucrose for 1 week, 
frozen in isopentane, and stored at −80°C until use.
immunohistochemistry
Immunohistochemistry was performed as described (37). 
Human sections (30–40  µm) were pre-incubated for 10  min 
with 5% H2O2 in 5% methanol in PBS, and for 24–48  h in 
PBS-0.3% Triton X-100, 2% normal donkey serum (NDS) 
at 4°C, with goat anti-P2X7 receptor antibody (1:100, 
peptide YETNKVTRIQSMNY-C from the N-terminus of 
human P2RX7 corresponding to amino acid residues 13-26, 
MyBioSource, San Diego, CA, USA). Sections were then incu-
bated with biotinylated donkey anti-goat antibodies (Jackson 
ImmunoResearch Europe Ltd., Suffolk, UK), followed by avi-
din–biotin–peroxidase reactions (Vectastain, ABC kit, Vector, 
Burlingame, CA, USA), using 3,3′-diaminobenzidine (Sigma-
Aldrich) as a chromogen. Some sections were counterstained 
with Luxol fast blue, in order to detect lesion types. Sections 
were mounted on poly-lysine slides and air dried for 24 h. The 
histological preparations were examined using an Axioskop 2 
light microscope (Zeiss). Images were taken with Neurolucida 
software (MBF Bioscience, USA).
immunofluorescence
Human sections (30–40  µm) were blocked with 10% NDS in 
0.3% Triton X-100 in PBS and incubated with primary antisera/
Table 2 | Summary of patients information.
case age (years) sex clinical diagnosis Disease duration (years) cause of death DTPi (h)
MS062 49 F SPMS 19 Respiratory infection 10
MS073 80 F SPMS 50 Bronchopneumonia 20
MS074 64 F SPMS 36 Gastrointestinal bleed/obstruction, aspiration pneumonia 7
MS076 49 F SPMS 18 Chronic renal failure, heart disease 31
MS079 49 F SPMS 23 Bronchopneumonia, MS 7
MS088 54 F SPMS 17 Bronchopneumonia 22
MS105 73 M SPMS 46 Pneumonia 8
MS114 52 F SPMS 15 Pneumonia, sepsis, pulmonary embolism 12
MS125 76 F SPMS 31 MS 13
MS128 78 F SPMS 50 Small bowel obstruction, pneumonia 22
MS136 40 M SPMS 9 Respiratory infection 10
MS154 34 F SPMS 11 Pneumonia 12
MS163 45 F SPMS 6 Urinary tract infection, MS 28
Demographic and clinical characteristics of MS cases at the time of tissue collection are reported.
DTPI, death-tissue preservation interval; SPMS, secondary progressive multiple sclerosis; MS, multiple sclerosis.
Table 3 | Antibodies used in this study.
antigen clone epitope (aa) Target Dilution source
CD45 61D3 a Leukocyte 1:100 Dako
CD14 biotinylated T29/33 a Monocytes 1:100 eBioscience
CD68 EBM11 a Macrophages/microglia 1:100 Dako
CD68 Polyclonal 100–354 Macrophages/microglia 1:200 Santa Cruz
GFAP 5C10 a Astrocytes 1:500 Novusbio
HLA-DP, DQ, DR (MHC II) CR3/43 a Macrophages/microglia 1:100 Dako
MBP 2 119–131 Mature oligodendrocytes/myelin 1:100 Chemicon
MCP-1 Polyclonal 62–89 CCL2 chemokine 1:20–1:1,000 ThermoFisher Scientific
P2X7-intracellular receptor, N-terminus Polyclonal 13–26 P2X7 receptor 1:100 MyBioSource
P2X7-extracellular receptor Polyclonal 136–152 P2X7 receptor 1:500 Alomone
P2X7-intracellular receptor, C-terminus Polyclonal 576–595 P2X7 receptor 1:500 Alomone
P2Y12 receptor human Polyclonal 324–342 Microglia 1:200 Anaspec
aNot specified in the data sheet.
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antibodies (Table 3) in 0.3% Triton X-100 and 2% NDS in PBS, 
for 24–48 h at 4°C and processed for double and triple immu-
nofluorescence. The secondary antibodies in 0.3% Triton X-100 
and 2% NDS in PBS were Cy3-conjugated donkey anti-goat 
IgG (1:100, Jackson Immunoresearch, West Grove, PA, USA, 
red), Cy5-conjugated donkey anti-mouse IgG (1:100, Jackson 
Immunoresearch, blue), Alexa Fluor® 488-AffiniPure donkey 
anti-mouse IgG (1:200, Jackson Immunoresearch, green), and 
Alexa Fluor® 488-AffiniPure donkey anti-rabbit IgG (1:200, 
Jackson Immunoresearch, green). In the case of biotinylated 
primary antibody CD14 and Lectin from Lycopersicon esculen­
tum (tomato) biotin conjugate (1:200, Sigma-Aldrich), Cy2-
streptavidin conjugated secondary antibodies (1:200, Invitrogen) 
were used.
Rat monocytes maintained in culture for 1 week were fixed 
with 4% paraformaldehyde for 20  min, permeabilized with 
0.1% Triton X-100 for 10  min, blocked in PBS/1% bovine 
serum albu min, and incubated in PBS/1% bovine serum 
albumin with anti-cluster of differentiation 68 (CD68, 1:200, 
Santa Cruz Biotechnology, CA, USA). The secondary antibody 
was Cy3-conjugated donkey anti-rabbit IgG (1:200, Jackson 
Immunoresearch). Cells were stained with Höechst 33342 
(1:1,000) and covered with coverslip in Fluoromount medium 
(Sigma-Aldrich) for confocal microscopy.
Quantification of CD68 immunoreactivity was performed 
with monocytes from rat spleen (from an average of six fields 
for each animal in each group), using Image J software. Data are 
expressed as optical density with respect to CFA group.
confocal Microscopy
Immunofluorescence analysis was performed by confocal laser 
scanning microscope (Zeiss, LSM700; Iena, Germany) equipped 
with four laser lines: 405, 488, 561, and 639 nm. Brightness and 
contrast were adjusted with Zen software (Zeiss).
Protein extraction and Western blotting
Six different snap-frozen blocks of frontal cortex from three 
independent SPMS cases, and one block from five different 
control cases were processed for protein extraction. Detergent-
soluble proteins were extracted with Ripa buffer (1% Nonidet 
P-40, 0.5% sodium deoxycholate, 0.1% SDS in PBS, contain-
ing protease inhibitors), using a micropestle. After a short 
sonication, the homogenates were incubated on ice for 1  h 
and centrifuged at 13,000  rpm for 10  min at 4°C. To extract 
detergent-insoluble proteins, the resulting pellet was resus-
pended in 0.5  M Tris HCl (pH 6.8) containing 2% w/v SDS 
(same volume as utilized for soluble protein extraction), and 
incubated at RT for 10 min. Insolubilized material in the pellet 
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Because the rat model of EAE is one among the most com-
monly used animal model for studying MS pathogenesis, by 
resembling particularly the acute form of the disease (41), 
we observed also in EAE monocytes, compared with CFA, a 
statistically significant decrease of P2X7R mRNA by RT-qPCR 
(Figure S1A in Supplementary Material), and of protein content 
by western blot analysis (Figure S1B in Supplementary Material). 
This occurs in parallel to the increase of the specific monocyte 
inflammatory marker IL-6 mRNA (Figure S1C in Supplementary 
Material), and of CD68 protein (Figure S1D in Supplementary 
Material).
inflammatory stimuli Down-regulate  
P2X7 receptor in Purified human, rat, 
and Mouse Monocytes
In order to mimic an inflammatory insult as it occurs in MS, 
monocytes from HD were challenged ex vivo with LPS or BzATP 
for 4 and 24 h. A significant decrease of human P2X7R/CD14 
bearing monocytes occurred after treatment for 24 h with LPS 
(Figures 1C,E, ~48% reduction) or BzATP (Figures 1D,E, ~63% 
reduction), as shown by FACS analysis. Western blot analysis 
confirmed these results in  vitro in rat cultured monocytes, 
showing down-regulation of P2X7R protein after 4 and 24 h of 
BzATP (Figure S1E in Supplementary Material, ~60 and 90% 
reduction, respectively) or LPS stimulation for 24 h (Figure S1E 
in Supplementary Material, ~45% reduction). Similar results 
were also obtained with mouse purified monocytes challenged 
in vitro with LPS or with BzATP. (Figure S1F in Supplementary 
Material).
P2X7 receptor is Present on Monocytes 
in blood Vessels of sPMs Frontal cortex
By immunohistochemistry and immunofluorescence analysis, 
we next analyzed the cortical tissue from 13 different cases of 
SPMS for the presence of P2X7R immunoreactivity and colo-
calization with specific cellular markers (Tables  2 and 3). In 
detail, we examined 1–2 different tissue blocks from all cases 
and inspected 4–10 different slices for each block. The tissue 
slices were studied in areas either presenting neuronal injury/
inflammation, or devoid of visible damage. We observed typical 
features of cortical demyelination and inflammation in all SPMS 
cases analyzed. Independent analysis was also performed in 
cortical tissue from four patients who died by non-neurological 
diseases (data not shown). In particular, by immunohisto-
chemistry (Figure  2A) the P2X7R immune-positive signal 
was found to delineate the plasma membrane of roundish cells 
distributed in distinct clusters in the cortical parenchyma. By 
immunofluorescence analysis, this roundish P2X7R immune-
positive signal (red) was found to colocalize with the CD45 
leukocyte marker (Figure  2B, green). By staining with Lectin 
(green) that specifically delineates endothelial vascular cells, we 
thus concluded that the roundish P2X7R-positive cluster cells 
were likely located inside blood vessels (Figures 2C,D) within 
the SPMS cortical parenchyma. Similar results were confirmed 
in all cases analyzed (Table  2) and in donors not deceased by 
neurological conditions (data not shown). By performing double 
(15,000 rpm for 15 min) was discarded. Protein quantification 
was performed from the supernatants by Bradford colorimetric 
assay (Biorad, Milan, Italy). Proteins (15 µg) were separated by 
electrophoresis on 10% SDS-PAGE and transferred to nitrocel-
lulose Hybond-C-extra membranes (Amersham Biosciences, 
Cologno Monzese, Italy). The filters were pre-wetted in 5% 
blocking agent in TBS-T (10 mM Tris pH 8, 150 mM NaCl, 0.1% 
Tween 20) and hybridized overnight with P2X7-extracellular 
epitope antibody (1:500, peptide KKGWMDPQSKGIQTGRC, 
corresponding to amino acids 136–152 of mouse P2X7 recep-
tor, Alomone Labs), in the absence or presence of the neutral-
izing immunogenic peptide used in a 1:1 protein ratio, and 
with monocyte chemoattractant protein-1 (MCP-1) antibody 
(1:1,000, ThermoFisher Scientific). The signals were detected 
with anti-rabbit horseradish peroxidase-conjugated antibody 
(1: 5,000), and developed by enhanced chemiluminescence 
(Amersham Biosciences), using Kodak Image Station (KDS 
IS440CF) and semi-quantitative analysis of which was per-
formed with Image J software.
Total proteins from control (n = 4), CFA (n = 3), and EAE 
(n  =  4) cultured rat monocytes and from control C57BL/6 
cultured mouse monocytes (n =  3) were obtained after lysis 
of cells on ice for 1  h in Ripa Buffer and centrifugation at 
14,000  rpm for 10  min at 4°C. Protein quantification was 
performed from the supernatants by Pierce™ BCA Protein 
Assay Kit (Thermo Scientific, Monza, MB, Italy). Proteins were 
separated by electrophoresis on 10% SDS-PAGE, transferred to 
nitrocellulose membranes, and processed for western blotting 
using P2X7-intracellular epitope antibody [1:500, peptide (C)
KIRKEFPKTQGQYSGFKYPY, corresponding to amino acids 
576–595 of rat P2X7 receptor, Alomone Labs]. The signal was 
detected with anti-rabbit horseradish peroxidase-conjugated 
antibody (1: 2,500), and developed by enhanced chemilu-
minescence (Amersham Biosciences). The bands of interest 
were visualized using Kodak Image Station (KDS IS440CF) 
and semi-quantitative analysis was performed with Image J 
software.
statistical analysis
Data are presented as mean ± SEM and statistical analysis was 
determined by ANOVA. Statistical differences between groups 
were verified by Student’s t-test. *p  <  0.05, **p  <  0.01, and 
****p < 0.0001 were considered statistically significant.
resUlTs
P2X7 receptor is Down-regulated in 
Monocytes during acute Ms and eae
Given the abundant expression of P2X7R on monocytes (38–40), 
in this work we firstly confirmed its presence in circulating 
monocytes from HD and then demonstrated its down-regulation 
in stable and acute MS patients compared with HD, by RT-qPCR 
(Figure  1A). Furthermore, FACS analysis confirmed a signifi-
cant decrease of CD14/P2X7R-positive monocytes only in MS 
acute patients compared with stable MS and HD conditions 
(Figure 1B).
FigUre 1 | P2X7 receptor (P2X7R) is down-regulated on circulating multiple sclerosis (MS) monocytes and on healthy donors (HD) monocytes after in vitro induced 
inflammation. (a) RT-qPCR analysis of P2X7R was performed with freshly isolated monocytes from MS stable (n = 8), acute patients (n = 8), and HD (n = 8). 
GAPDH was used for normalization. (b) Flow cytometry analysis was used to isolate cluster of differentiation 14 (CD14)-positive monocytes and P2X7R-CD14 
double-positive cells within freshly isolated peripheral blood mononuclear cells from acute, stable MS patients, and HD. Cumulative data of P2X7R-positive cells 
within monocytes are reported as % mean ± SEM (n = 5). Statistical significance was calculated by ANOVA-Student’s t-test, ****p < 0.0001 and *p < 0.05. 
Circulating monocytes purified from HD were incubated with inflammatory lipopolysaccharide (250 ng/ml) (c) or 2′3′-O-(4-benzoyl-benzoyl)adenosine5′-
triphosphate (250 µM) (D) for 4 and 24 h. Flow cytometry analysis and representative plots of P2X7R expression are shown (c,D), together with cumulative  
data from three independent experiments are presented (e). Statistical significance was calculated by ANOVA-Student’s t-test *p < 0.05, **p < 0.01.
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and triple confocal immunofluorescence of these cluster cells 
with the CD14 monocyte/macrophage marker (Figures 2E–G, 
green), we demonstrated only partial colocalization with P2X7R 
immunoreactivity (Figures  2E–G, in red), being the P2X7R 
signal apparently absent from CD14-positive cells (white arrows) 
that are proximal to the endothelium of the blood vessels and 
FigUre 2 | P2X7 receptor (P2X7R) is present on monocytes in blood vessels of secondary progressive multiple sclerosis (SPMS) frontal cortex.  
(a) Immunohistochemistry on sections from human frontal cortex shows roundish P2X7R-positive cells distributed within distinct clusters throughout the entire 
SPMS tissue. Confocal double immunofluorescence analysis of these clusters exhibits colocalization of P2X7R protein (red) with CD45 leukocyte marker [(b), green]. 
Staining with Lectin from Lycopersicon esculentum for vascular endothelial cells [(c,D), green] clearly shows the presence of P2X7R-positive roundish cells (red) 
within the lumen of blood vessels (asterisk). Double immunofluorescence of P2X7R-positive clusters shows colocalization of P2X7R (red) with cluster of 
differentiation 14 (CD14) monocyte/macrophage marker [(e), green]. Confocal triple immunofluorescence analysis is then performed with antibodies for  
CD14 [(F,g), green], P2X7R [(F,g), red], and microglia/macrophages markers CD68 (F) or major histocompatibility complex II [(g), blue]. The asterisk  
always indicates the lumen of blood vessels, arrows indicate P2X7R-negative cells, and arrowheads P2X7R-positive cells.
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that are simultaneously positive for CD68 (Figure 2F, blue, white 
arrows) or for the major histocompatibility complex II (MHC 
II) (Figure  2G, blue, white arrows) macrophage/microglia 
markers. In all the sections analyzed, P2X7R is present only 
on few perivascular double CD14- and MHC II-positive cells 
(Figure 2G, arrowheads, white signal).
FigUre 3 | P2X7 receptor (P2X7R) is present on astrocytes in the parenchyma of secondary progressive multiple sclerosis (SPMS) frontal cortex. Confocal  
analysis of SPMS frontal cortex parenchyma shows absence of colocalization of P2X7R (red) with P2Y12R [(a), green], major histocompatibility complex II (MHC II) 
[(b), blue], and myelin basic protein [(c), blue], but the presence of merged P2X7R/glial fibrillary acidic protein signals (D–F). P2X7R/MHC II-positive signal is also 
visible but confined in the lumen of a blood vessel [(b), arrow, pink]. Immunohistochemistry analysis of cortical parenchyma reveals the abundant presence of P2X7R 
in GM on interlaminar (g) and protoplasmic astrocytes (e), and in white matter on fibrous astrocytes (i,J). In (J), astrocytic “vascular feet” are visible adjacent to the 
blood vessel walls (arrows).
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P2X7 receptor is Present on astrocytes in 
the Parenchyma of sPMs Frontal cortex
We next investigated the distribution of P2X7R in the corti-
cal parenchyma outside from the blood vessels. Double 
immu nofluorescence confocal analysis indicated the absence 
of colocalization of P2X7R (red) with P2Y12R (green) or MHC 
II (blue) (markers, respectively, of quiescent or reactive/active 
macrophages/microglia, Figures 3A,B) (42, 43), or with myelin 
FigUre 4 | P2X7 receptor (P2X7R) immunoreactivity is increased with 
astrogliosis in white matter (WM) of secondary progressive multiple sclerosis 
(SPMS) frontal cortex parenchyma. Immunohistochemistry analysis of two 
adjacent WM fields from SPMS frontal cortex characterized, respectively, by 
hypertrophic astrocytes (b) and glial scar (c) reveals a noteworthy increase  
in P2X7R-positive astrocytes (b,c), compared with control case (a).
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basic protein (MBP) (blue, marker of myelin fibers, and oligo-
dendrocyte cell bodies, Figure  3C). The receptor was instead 
strongly expressed in glial fibrillary acidic protein (GFAP)-
positive astrocytes present in both gray (GM, Figures  3D–F) 
and white matter (WM) (not shown) of both control and MS 
patients. Moreover, immunohistochemistry studies corroborated 
the presence of P2X7R in the soma and fibers of interlaminar 
astrocytes (Figure 3G) present in GM cortical layer I that spread 
prominent, long, and unbranched processes throughout the 
layers of the cortex, and moreover in protoplasmic astrocytes 
(Figure 3H) that are well-organized in GM into non-overlapping 
spatial domains. In WM, we also observed a strong P2X7R signal 
in fibrous astrocytes (Figure 3I) that exhibit unbranched cellular 
processes and that often protrude “vascular feet” (44) that are 
physically connected to the external capillary walls (Figure 3J).
With the aim of further characterizing P2X7R expression 
and modulation in astrocytes, we acquired images from adjacent 
immunohistochemical fields within the same cortical sections 
and compared them with control cases (Figures 4A–C). Respect 
to control (Figure  4A), we observed a remarkable increase in 
P2X7R-positive astrocytes in different WM zones of SPMS corti-
cal tissue presenting high levels of astrogliosis (Figure 4B) and 
glial scar formation (Figure 4C). In detail, in SPMS cortex, P2X7R 
immunoreactivity distinguished an area (Figure 4B) with strong 
reactive astrogliosis, intense cellularity, prominent hypertrophy, 
proliferation, and overlapping of astrocyte processes causing 
the disruption of distinctive astrocyte domains. Furthermore, 
the P2X7R signal also identified a zone very rich in parallel and 
interconnected fibers highlighting a prominent glial scar, where 
astrocytes displayed densely intersecting processes characterized 
by intense double P2X7R/GFAP-positive immunoreactive signal 
(Figure 4C; Figure S2 in Supplementary Material).
expression of P2X7 receptor in active  
or inactive subpial lesions of sPMs 
Frontal cortex
Although MS is still widely considered a WM disease, demyelina-
tion is also prominent in GM. SPMS phase is characterized by 
subpial lesions that are highly abundant in progressive stages of 
MS, closely to the subarachnoid space, involving either part of 
a cortical gyrus, or often covering adjacent gyri (45). By triple 
immunofluorescence confocal analysis, we have characterized a 
subpial lesion with various degrees of inflammatory reaction and 
demyelination and observed different features of P2X7-positive 
immunoreactivity. In detail, the presence of profuse reactive 
MHC II-positive monocytes/macrophages/microglia (blue, 
Figure 5B) and the permanence of MBP-positive myelin fibers 
(green, Figure 5C) defined a chronic active lesion characterized 
by abundant P2X7R-positive signal (red, Figure 5A and insets) 
that highlighted a zone of intense cellularity and astrogliosis 
(see merged P2X7R-GFAP signal in the inset). On the other 
hand, in an area where MHC II (blue, Figure  5E) and MBP 
(green, Figure 5F) signals both decreased indicating a chronic 
inactive lesion (46), the P2X7R-positive immunoreactivity (red, 
Figure 5D) identified a zone very rich in fibers typical of a glial 
scar (see merged P2X7R-GFAP signal in the inset).
Ms Pathology alters P2X7 receptor 
mrna and Protein levels
To further investigate if SPMS progression modifies the P2X7R 
content, we analyzed total cell extracts from frontal cortex, by 
RT-qPCR and western blotting. A statistically significant increase 
of P2X7R mRNA was observed in SPMS patients, compared 
with controls (Figure  6A). Similar results were confirmed by 
immunoblotting with a P2X7R antibody raised against an extra-
cellular epitope of the mouse P2X7R (corresponding to amino 
acid 136–152). In human frontal cortex tissue, we recognized 
FigUre 5 | P2X7 receptor (P2X7R) expression in both active and inactive subpial lesions of secondary progressive multiple sclerosis (SPMS) frontal cortex. 
Confocal triple immunofluorescence analysis performed with antibodies for P2X7R [(a,D), red], major histocompatibility complex II (MHC II) [(b,e), blue], and myelin 
basic protein (MBP) [(c,F), green] on SPMS frontal cortex sections, shows a chronic active subpial lesion (a–c) with abundant glial fibrillary acidic protein (GFAP)/
P2X7R-positive signal (a, inset), with reactive MHC II-positive monocyets/macrophages/microglia (blue) and with MBP-positive myelin fibers (green). In a chronic 
inactive lesion (D–F), an intense GFAP/P2X7R glial scar is shown [(D), inset], with decreased MHC II-positive [(e), blue] and MBP-positive [(F), green] 
immunoreactivities.
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three specific protein bands with estimated sizes in the ranges 
52–72, 72–95, and 95–140  kDa, perhaps corresponding to the 
different P2X7 isoforms, and that were moreover abolished by 
the P2X7R neutralizing immunogenic peptide (data not shown). 
In addition, particularly the 95–140 kDa P2X7R was found sig-
nificantly up-regulated in both detergent-soluble and -insoluble 
fractions of SPMS tissue extracts respect to controls, while the 
52–72  kDa P2X7R was significantly up-regulated only in the 
detergent-insoluble fraction of SPMS extracts, with a trend to 
increase in the detergent-soluble fraction (Figures 6B,C).
P2X7 receptor colocalizes with McP-1 
chemokine in human Frontal cortex
Because the up-regulation of MCP-1 in astrocytes is demon-
strated to have an important role in recruiting leukocytes in the 
FigUre 6 | P2X7 receptor (P2X7R) mRNA and protein are augmented in secondary progressive multiple sclerosis. (a) Total RNA was extracted from three different 
snap-frozen blocks from MS patients (cases MS114, MS125, and MS163) and six controls (cases C12–101, C12–112, C13–010, C13–022, C14–069, and 
C14–053) and the expression of P2X7R mRNA was examined by RT-qPCR. Cortical protein extracts (15 μg/well) from different tissue blocks (A5C3, A5B3, A3B1, 
A1A2, A2A1, and A2B2) of MS cases MS114, MS125, and MS163 were analyzed by western blotting for the modulation of P2X7R, with respect to control cases 
(C12–101, C12–112, C13–010, C13–022, and C14–069), in both detergent-soluble (b) and -insoluble fractions (c). GAPDH was used for protein normalization. 
Statistical significance was calculated by Student’s t-test, *p < 0.05, **p < 0.01. Results are shown as mean ± SEM.
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CNS during MS (47–49), and the P2X7R agonist BzATP increases 
MCP-1 expression in astrocytes through P2X7R activation (50), 
we evaluated the expression of this chemokine in our human 
SPMS cortical tissue and its potential colocalization with P2X7R 
on astrocytes. Western blot analysis of protein extracts from 
control and SPMS patients, demonstrated a strong up-regulation 
(about twofold increase) of MCP-1 in MS respect to control 
(Figure  7). Moreover, triple immunofluorescence confocal 
analysis showed an unambiguous intense colocalization (white 
signal) among P2X7R (red), MCP-1 (green), and GFAP (blue) 
FigUre 7 | Monocyte chemoattractant protein-1 (MCP-1) chemokine is 
up-regulated in secondary progressive multiple sclerosis frontal cortex. Equal 
amount of total protein extracts of cortical tissue (15 μg/well) from different 
tissue blocks (A5C3, A5B3, A3B1, A1A2, A2A1, and A2B2) of multiple 
sclerosis (MS) cases MS114, MS125, and MS163 was analyzed by western 
blotting for the expression of MCP-1 chemokine with respect to control 
cases (C12–101, C12–112, C13–010, C13–022, and C14–069). β-actin was 
used for protein normalization. Statistical significance was calculated by 
Student’s t-test, *p < 0.05. Results are shown as mean ± SEM.
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proteins, both in control (Figures  8A–D) and SPMS tissues 
(Figures  8E–H), and moreover a strong up-regulation of both 
P2X7R and MCP-1 during astrogliosis occurring in WM of SPMS 
patients (Figures 8E–H).
DiscUssiOn
The adhesion of leukocytes to endothelial cells and their migration 
into the CNS parenchyma through the blood–brain barrier is a 
critical step in the development of brain inflammation. Although 
many types of immune cells are involved in this process during 
MS progression, activated monocytes are believed to be one of 
the first phenotypes to reach the brain and initiate neuroinflam-
mation. Because P2X7R is highly expressed in immune cells of 
the monocyte–macrophage lineage (38), and activation of P2X7R 
triggers multiple responses affecting the intensity and duration of 
innate immune and inflammatory reactions in lymphoid leuko-
cytes (51, 52), the aim of this work was to characterize the P2X7R 
in MS peripheral monocytes and cortical parenchyma. We found 
that P2X7R protein expression is down-regulated during the 
acute phase of the disease both in patients and rat EAE monocytes 
and, moreover, the protein levels of the receptor are reduced in 
human, rat, and mouse healthy monocytes challenged in  vitro 
with pro-inflammatory stimuli. Based on these results, we can 
hypothesize that high-P2X7R expression might be perhaps del-
eterious for monocyte survival, and therefore the receptor might 
be reduced during MS to contribute to initiate and propagate the 
neuroinflammation. Confirming our hypothesis, overexpression 
of P2X7R is induced in human monocytes/macrophages infected 
with high-apoptogenic M. tuberculosis, in a suicide-leading track 
as an attempt to reduce mycobacterial viability (53). Similarly, 
P2X7R activation with resultant Ca2+ overload triggers death also 
of native mouse monocytes/macrophages (18). Finally, Treg cells 
with high levels of P2X7R expression are prompted to die (54) 
when the clearance of excessive toxic ATP is less efficient, as in 
MS patients with reduced levels of the CD39 ectonucleotidase 
enzyme (55). Therefore, when high-extracellular concentrations 
of ATP are released in damaged areas as a result of tissue injury, 
the down-regulation of P2X7R expression as we demonstrated 
here, seems an attempt to limit a long-lasting opening of P2X7R 
channel and massive Ca2+ entry, with the final aim of sustain-
ing monocyte survival and, in the case of MS, enhancing pro-
inflammatory signals and further damage into the CNS. While 
this mechanism would apparently diverge from what observed in 
Behçet’s disease where P2X7R is instead up-regulated in mono-
cytes from patients (56), it is however conserved in pathological 
conditions other than MS, and in additional cell phenotypes. 
Reduction of P2X7R expression in PBMCs leading to intracel-
lular calcium dysregulation occurs for instance during ALS (40), 
a neuroinflammatory/neurodegenerative disease also involving 
P2X7R (14, 57, 58); P2X7R−/− oligodendrocytes show increased 
survival in EAE (31), and increased survival of oligodendrocyte 
precursors occurs also after down-regulation of P2X7R during 
hypoxia ischemia (59).
We have next looked at P2X7R expressed in CNS tissue, 
and found that the P2X7R is localized on CD45/CD14-positive 
monocytes that are visible in the lumen of blood vessels of the 
cortical parenchyma. Remarkably, the receptor was progressively 
lost on both CD14/CD68- or CD14/MHC-II-positive cells neigh-
boring the endothelium of the blood vessels and perhaps entering 
into the CNS, thus corroborating the hypothesis that inflamma-
tory stimuli in the peripheral tissue might trigger a secondary 
autocrine/paracrine down-regulation of P2X7R expression, with 
the final aim of boosting and propagating the neuroinflammation 
into the CNS.
Although these results validate the renowned importance of 
purinergic P2X7R-dependent signaling in neuroinflammatory 
conditions, the impact of this receptor in the pathogenesis and 
clinical aspects of MS is still to be defined. In order to clarify 
how P2X7R down-regulation in monocytes might correlate to 
inflammatory lesions and disease progression, we investigated 
its expression also in autoptic cortical tissue from SPMS donors. 
In contrast to optic nerve from rat EAE (31) and MS patients 
(32), in SPMS frontal cortex we found P2X7R absent from 
myelin fibers and oligodendrocyte cell bodies. Differently 
from MS spinal cord (21), in SPMS frontal cortex we did not 
detect P2X7R expression on resting and activated microglia. 
In contrast to other MS cerebral areas, in SPMS frontal cortex 
we found P2X7R also absent from neurons, although we con-
firmed its presence in astrocytes (23). In particular, abundant 
P2X7R immunoreactivity was found localized on interlaminar 
FigUre 8 | Monocyte chemoattractant protein-1 (MCP-1) chemokine colocalizes with P2X7 receptor (P2X7R) on astrocytes in secondary progressive multiple 
sclerosis (SPMS) frontal cortex. Triple immunofluorescence confocal analysis performed on sections of frontal cortex from control (a–D) and SPMS (e–h) with 
antibodies for P2X7R [(a,e), red], MCP-1 [(b,F), green], and glial fibrillary acidic protein [(c,g), blue] shows colocalization [(D,h), white signal] and strong 
up-regulation of signals in white matter of SPMS (e–h).
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FigUre 9 | Spatiotemporal profile of P2X7 receptor (P2X7R) expression in multiple sclerosis (MS). The cartoon describes that P2X7R is down-regulated in 
monocytes during their activation and extravasation from blood vessel to MS cerebral cortex, while the receptor and the monocyte chemoattractant protein-1 
chemokine are up-regulated on MS astrocytes concurrently with increased glial fibrillary acidic protein signal and glial scar formation.
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and protoplasmic astrocytes of gray matter, and on fibrous 
astrocytes of white matter. Noticeably, P2X7R-positive astrocytes 
augmented in cortical tissue of SPMS patients in proximity of 
lesions. By further extending previous results, these observations 
thus indicate that P2X7R localization in the CNS and modulation 
in MS is strictly tissue- and specie-specific.
Being P2X7R per se involved in several and sometimes opposite 
functions (15), its presence on astrocytes playing a dual role in MS 
by either promoting inflammation and impeding tissue repair, or 
protecting healthy tissue from adjacent zones of strong inflam-
mation (60), can designate its potential role in several distinct 
actions. Indeed, we might hypothesize that in astrocytes of SPMS 
frontal cortex, the up-regulation of P2X7R might contribute to 
build the parenchyma micro-architecture, being the receptor 
expressed by interlaminar, protoplasmic, and fibrous astrocytes 
(61–63). P2X7R could also regulate extracellular K+ homeostasis 
and participate to the removal of excess glutamate, by directly 
modulating K+ efflux (64, 65). Moreover, increased P2X7R might 
influence the connectivity of neuronal circuits, being the receptor 
known to be involved in the control of myelination (29), or provide 
metabolic support to neurons, by regulating the lipid metabolism 
pathway (66). Finally, P2X7R might participate to preserve the 
blood–brain barrier (60), since we demonstrated here its expres-
sion in astrocytes protruding their vascular feet on external capil-
lary walls. However, the specific role of P2X7R up-regulation on 
SPMS astrocytes might be regulated by several features, including 
the specific disease stage, the presence of active or inactive lesions 
characterized, respectively, by P2X7R-positive astrogliosis or 
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P2X7R-positive glial scar, the interaction with various cell types, 
such as for instance the endothelial cells. Extracellular soluble 
factors might also influence the diverse cellular reactivity to 
P2X7R activation during MS. For instance, extracellular ATP is 
known to induce the secretion from astrocytes of MCP-1 (50), 
a crucial chemokine up-regulated after CNS trauma (67), and 
known to have an important role in engaging monocyte-rich 
infiltrates into the CNS during MS (47–49). In addition, BzATP 
increases in  vitro MCP-1 levels in cultured astrocytes directly 
through P2X7R activation (50). On this regard, the increase of 
MCP-1 protein that we have demonstrated in SPMS cortical 
extracts might likely be related to the up-regulation of P2X7R in 
astrocytes. Supporting this possibility, we have also demonstrated 
that MCP-1 is induced in cortical MS protein extracts and indeed 
colocalizes with P2X7R on astrocytes in SPMS frontal cortex.
By considering our results in the context of previous knowl-
edge, we can therefore formulate the following hypothesis: extra-
cellular ATP is increased in CNS tissue as an alarm signal due to 
progressive homeostasis loss during MS; astrocytes up-regulate 
P2X7R and MCP-1; this last functions as attractant for peripheral 
monocytes which in turn down-regulate P2X7R to guarantee 
their survival and invasion into the CNS tissue, thus contribut-
ing to the detrimental effects of neuroinflammation (Figure 9). 
Further work will verify our hypothesis and the time-cause cor-
relation of these events. By gaining insights into P2X7R dynamics 
and signaling, we expect to contribute to further discern some 
molecular aspects of MS.
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FigUre s1 | P2X7R is downregulated on spleen monocytes from rat EAE, and 
on rat and mouse spleen monocytes after pro-inflammatory induction with LPS 
and BzATP. CFA and EAE purified rat monocytes were subjected to RT-qPCR (a) 
and western blot analysis (b) for evaluation of P2X7R expression. Data in (a,b) 
represent means ± SEM (n = 4 in EAE and n = 3 in CFA). RT-qPCR (c) and 
immunofluorescence analysis (D), respectively for IL-6 mRNA and CD68 protein 
is shown. Data represent means ± SEM (n = 3 in EAE, and n = 3 in CFA). 
Statistical significance was calculated by Student’s t-test, *p < 0.05 compared to 
CFA. Western blot analysis of P2X7R expression after in vitro administration of 
pro-inflammatory BzATP (250 μM) or LPS (100 ng/ml) for 4 and 24 h to purified 
rat (e) and mouse (F) monocytes. Equal amount of total protein (3–6 μg/well) 
was analyzed in each sample and GAPDH was used for protein normalization. 
Results are shown as means ± SEM, n = 4 for rat and n = 3 for mouse. 
Statistical significance was calculated by Student’s t-test, *p < 0.05, **p < 0.01 
compared to T0.
FigUre s2 | P2X7R/GFAP-positive astrocytes characterize a glial scar in WM 
chronic lesion of SPMS frontal cortex. Confocal double immunofluorescence 
analysis performed with antibodies for P2X7R (red) and GFAP (blue) on SPMS 
frontal cortex sections, shows a chronic lesion in WM characterized by the 
presence of a glial scar with abundant P2X7R/GFAP double-positive fibers.
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